Overview Financials News + Filings IR Vault Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Appointed director
|
|
Merck & Co., Inc. (MRK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/25/2021 |
GN
| SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Pandion Therapeutics, Inc. Buyout |
| 09/08/2020 |
GN
| Biopharma Leaders Unite to Stand with Science |
| 08/11/2020 |
GN
| Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020 |
| 01/28/2020 |
GN
| BriaCell's Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston |
| 01/13/2020 |
GN
| BriaCell Provides Update on Remarkable Responder |
| 01/09/2020 |
GN
| BriaCell Outlines New High Responding Patient Group ‘Biomarker' Based on Cancer Grade |
| 01/02/2020 |
GN
| BriaCell Completes Share Consolidation |
| 12/20/2019 |
GN
| NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®) |
| 12/17/2019 |
GN
| BriaCell to Present at Biotech Showcase™ 2020 in San Francisco |
| 12/13/2019 |
GN
| BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium® |
| 11/12/2019 |
GN
| BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th |
| 10/24/2019 |
GN
| BriaCell Announces Voting Results of the Special Meeting of Shareholders |
| 10/08/2019 |
GN
| BriaCell Therapeutics Corp. to File Amendment to Management Information Circular |
| 10/01/2019 |
GN
| Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month |
| 09/25/2019 |
GN
| BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy' Issue in Prestigious Journals |
| 09/20/2019 |
GN
| BriaCell Announces Private Placement of up to $600,000 |
| 09/19/2019 |
GN
| BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA® |
| 09/16/2019 |
GN
| BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia |
| 09/09/2019 |
GN
| BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49 |
| 08/27/2019 |
GN
| BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 |
| 08/12/2019 |
GN
| BriaCell Appoints Richard J. Berman to Board of Directors |
| 07/23/2019 |
GN
| BriaCell Announces $350,000 Equity Investment by Board of Directors |
| 04/23/2019 |
GN
| BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston |
| 04/03/2019 |
GN
| BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity |
| 04/02/2019 |
GN
| BriaCell Announces Clinical Trial Collaboration Agreement with Incyte |
| 04/01/2019 |
GN
| BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million |
| 03/26/2019 |
GN
| BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting |
| 03/07/2019 |
GN
| BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire |
| 02/26/2019 |
GN
| BriaCell Announces C$500,000 Equity Investment by BriaCell Director |
| 02/21/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders |
| 02/20/2019 |
GN
| New Research: Key Drivers of Growth for DISH Network, Avon Products, Merck & Co., Laredo Petroleum, Health Insurance Innovations, and Bruker — Factors of Influence, Major Initiatives and Sustained Production |
| 02/15/2019 |
GN
| Cerecor Announces CERC-301 Granted U.S. Patent |
| 01/02/2019 |
GN
| BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference |
| 12/28/2018 |
GN
| Analysis: Positioning to Benefit within General Motors, RE/MAX, Genworth Financial, Merck & Co., Aerojet Rocketdyne, and Fluor — Research Highlights Growth, Revenue, and Consolidated Results |
|
|
|